Literature DB >> 10586338

Treatment of multicentric Castleman's disease complicated by the development of non-Hodgkin's lymphoma with high-dose chemotherapy and autologous peripheral stem-cell support.

R Advani1, R Warnke, S Rosenberg.   

Abstract

BACKGROUND: Castleman's disease or angiofollicular lymph node hyperplasia is a rare entity with a localized/unicentric or a generalized/multicentric presentation. While surgery is curable for most localized presentations, there is limited information regarding the optimal management of the multicentric type. The latter type is associated with a poor prognoses and can be associated with the development of lymphoma and infections. PATIENTS AND METHODS: In this report we describe a case of multicentric Castleman's disease who failed steroids and chemotherapy and developed a follicular mixed lymphoma. He was treated with high-dose chemotherapy with autologous stem-cell support and remains disease at four years of follow-up.
CONCLUSIONS: A long-term durable remission may be possible with high dose chemotherapy with stem-cell support. This treatment modality should be considered an option in the management of multicentric Castleman's disease.

Entities:  

Mesh:

Year:  1999        PMID: 10586338     DOI: 10.1023/a:1008366721816

Source DB:  PubMed          Journal:  Ann Oncol        ISSN: 0923-7534            Impact factor:   32.976


  3 in total

1.  Autologous stem cell transplantation in a rare multicentric Castleman disease of the plasma cell variant.

Authors:  Yuval Tal; Guy Haber; Matan J Cohen; Micci Phillips; Gail Amir; Dina Ben-Yehuda; Arie Ben-Yehuda
Journal:  Int J Hematol       Date:  2011-03-26       Impact factor: 2.490

Review 2.  Treatment of Castleman's disease.

Authors:  Angela Dispenzieri; Morie A Gertz
Journal:  Curr Treat Options Oncol       Date:  2005-05

3.  Diffuse Large B-cell Lymphoma during Corticosteroid Therapy for TAFRO Syndrome.

Authors:  Eiko Ohya; Minoru Mizutani; Haruna Sakaguchi; Takao Sekine
Journal:  Intern Med       Date:  2016-10-01       Impact factor: 1.271

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.